Needlestick Safety and Prevention Act

1. Needlestick Safety and Prevention Act Directed OSHA to revise BBP standard • Effective 4/18/01 • Compliance directive 11/27/01 • Requires use of engineering and work practice controls • Sharps safety devices included as engineering controls • Alternatives to needles are preferable • Document implementation in written plan • Review at least annually • Maintain detailed sharps injury log • Include device type & brand • Involve frontline workers

2. Statement of employer policy Designation of responsible employees Determination of employee exposures Implementation Standard (universal) precautions Engineering controls Work practices controls Personal protective equipment Training Hepatitis B immunizations Implementation HB surveillance (optional) Post-exposure evaluation and follow-up Housekeeping Labeling Mandated use of needles and other sharps with integrated safety features Safety Device Evaluation Committee Documentation of waivers Recordkeeping and reporting Bloodborne PathogensExposure Control Plan

3. Recombinant DNA vaccine available since 1986 From yeast cells Subunit HBsAg 1.0 ml IM given at 0, 1 and 6 months Accelerated 0, 1, 2 and 12 months For HCWs, document immunity anti-HBS 2-6 months post-vaccination 6 doses maximum Once immune, no boosters HBV Preexposure Prophylaxis

4. Recordkeeping Rule • Effective 1/1/02 • New OSHA forms 300 log, 300A summary and 301 incident report • Expanded general recordkeeping requirements • May use new log for recording contaminated sharps injuries if • Record all data required, including brand • Able to segregate sharps info from log for privacy concerns

5. Joint Commission on Accreditation of Healthcare Organizations Preventing Needlestick and Sharps Injuries - Sentinel Event Alert, Issue 22, August 2001 • Cites and reviews NIOSH Alert and the Needlestick Safety and Prevention Act. • “In April 2002, JCAHO will begin assessing organizational compliance with the new provisions of the Needlestick Safety and Prevention Act.”

6. “The prevention of occupational diseases is primarily the function of the industrial management, secondarily, the function of the plant physician. In an ideal industrial establishment the two work together; the physician is conversant with all the processes of manufacture and is therefore able to link up the disturbances of health he observes among the workers with the processes in which they are engaged. He cooperates with management in the effort to introduce safeguards .... He is, however, in a subordinate position and therefore the prime responsibility in the prevention of occupational disease lies with the management, which has the last word in regard to methods of work, substances used, and equipment for the prevention of disease.” Alice Hamilton, MD & Harriet L. Hardy, MD Industrial Toxicology, 1949

7. Prevention of Work-related BBP Infection Haddon, 1970

8. Controlling Exposures In order of preference • Substitution • Isolation or enclosure • Ventilation (general/dilution & local exhaust) • Work and hygiene practices • Personal protective equipment (last line of defense) T R A I N I N G

9. Types of Safety Features Chiarello, 1995

10. Design Features of a Safer Needle Device • Barrier between hands and needle after use • Allow or require worker’s hands to remain behind needle at all times • Integral part of device and not accessory • Be in effect before disassembly and remain in effect after disposal • Be simple, self-evident to operate and require little or no training FDA, 1992, 1995

11. Click for larger picture

12. MMWR 1/17/97

13. Recommended Personal Protective Equipment Y=Yes, N=No, M1=Yes if splashing likely, M2=Yes if soiling likely, M3=At certain times CDC 1989

14. Management of Occupational Blood Exposures • Provide immediate care to the exposure site • Wash wounds and skin with soap and water. • Flush mucous membranes with water. • Determine risk associated with exposure by • Type of fluid (e.g., blood, visibly bloody fluid, other potentially infectious fluid or tissue, and concentrated virus) and • Type of exposure (i.e., percutaneous injury, mucous membrane or nonintact skin exposure, and bites resulting in blood exposure).

15. Management of Occupational Blood Exposures • Evaluate exposure source • Assess risk of infection using available information. • Test known sources for HBsAg, anti-HCV, and HIV antibody (consider using rapid testing). • For unknown sources, assess risk of exposure to HBV, HCV, or HIV infection. • Do not test discarded needles or syringes for virus contamination.

16. Management of Occupational Blood Exposures • Evaluate the exposed person • HBV immune status • Tetanus prophylaxis • Baseline lab tests for HCV, HIV, chemistry profile, complete blood count, urinalysis, pregancy test PRN • Give PEP for exposures posing risk of infection transmission

17. Always indicated unless Documented immune Waiver signed HBV Postexposure Prophylaxis

18. Hepatitis B Virus Postexposure Prophylaxis Click for larger picture

19. HCV Postexposure Prophylaxis

20. Depends on Type of exposure Severity Volume Source HIV status Prophylactic treatment May not be warranted Basic regimen Expanded regimen HIV Postexposure Prophylaxis

21. HIV-Positive Class 1 Asymptomatic Known low viral titer, <1500 RNA copies/ml HIV-Positive Class 2 Symptomatic AIDS Acute seroconversion Known high viral load HIV Infection Status

22. Selected HIV PEP Regimens BASIC REGIMEN • Zidovudine (Retrovir™; ZDV; AZT) + Lamivudine (Epivir™; 3TC); available as COMBIVIR™ • ZDV: 600 mg per day, in 2 or 3 divided doses • 3TC: 150 mg twice daily EXPANDED REGIMENBasic regimen plus • Indinavir (Crixivan™; IDV) • 800 mg every 8 hours, on an empty stomach

23. Recommended HIV Postexposure Prophylaxis for Percutaneous Injuries CDC. MMWR 2001.

24. Recommended HIV Postexposure Prophylaxis for Mucous Membrane and Non-intact Skin Exposures CDC. MMWR 2001.

25. Reported Failure of Combination Drug PEP to Prevent HIV Infection in HCWs Exposed to HIV-Infected Blood

26. Management of Occupational Blood Exposures • Initiate HIV PEP as soon as possible, preferably within 2 hours of exposure • Offer pregnancy testing to all women of childbearing age not known to be pregnant • Seek expert consultation if viral resistance suspected • HIV PEP for 4 weeks if tolerated

27. Management of Occupational Blood Exposures • Provide counseling • Emotional effects • Risks of transmission • Medications, including adherence • Advise exposed persons to seek medical evaluation for any acute illness occurring during follow-up • Perform follow-up testing • Monitor for adverse effects • Seroconversion

28. Sample Protocol for Follow-up if on HIV PEP Medications

29. Primary Side Effects of Antiretroviral Agents

30. Compliance with HIV PEP N=449 subjects with follow-up at 4-6 weeks HIV PEP Registry, 3/31/99

31. Reasons HIV PEP Discontinued N=197 HIV PEP Registry, 3/31/99

32. Management of Occupational Blood & Body Fluids Exposures Summary • Provide immediate care to the exposure site. • Determine risk associated with exposure. • Evaluate the exposed person. • Give PEP for exposures posing risk of infection transmission. • Provide counseling. • Perform follow-up testing.

33. Resources